Results 21 to 30 of about 89 (70)

Genome‐Wide Protein Interaction Analysis in Parasitic Gyrodactylus Flatworms–Fish Hosts System and Drug Target Identification

Advanced Science, Volume 12, Issue 45, December 4, 2025.
Genomic data offer a powerful tool for studying the molecular interactions between parasites and their hosts, but they remain scarce for parasitic monogenean flatworms. This study presents the first high‐quality phased genome assembly for monogeneans (Gyrodactylus kobayashii), and uses it to predict key interacting proteins between monogenean parasite ‐
Dong Zhang, Jie‐Mei Zhao, Chuan‐Yu Xiang, Yi‐Wen Ma, Hong‐Peng Lei, Yu‐Ying Shi, Shun Zhou, Xiaofei Zeng, Jinsong Chen, Fei Liu, Benhe Zeng, Rui Song, Ye Hu, Feng Zhang, Xiang Liu, Wen‐Xiang Li, Gui‐Tang Wang, Ivan Jakovlić   +17 more
wiley   +1 more source

In silico, in vitro and ex vivo characterization of cystic fibrosis transmembrane conductance regulator pathogenic variants localized in the fourth intracellular loop and their rescue by modulators

British Journal of Pharmacology, Volume 182, Issue 24, Page 6063-6080, December 2025.
Background and Purpose Cystic fibrosis (CF) is due to loss‐of‐function variants of the CF transmembrane conductance regulator (CFTR) channel. The most effective treatment for people with CF carrying the F508del mutation is the triple combination of elexacaftor–tezacaftor–ivacaftor (ETI).
Emanuela Pesce, Valeria Tomati, Valeria Capurro, Mariateresa Lena, Cristina Pastorino, Miro Astore, Serdar Kuyucak, Benoit Chevalier, Elvira Sondo, Federico Cresta, Alice Dighero, Vito Terlizzi, Cristina Fevola, Stefano Costa, Maria Cristina Lucanto, Valeria Daccò, Laura Claut, Francesca Ficili, Benedetta Fabrizzi, Renata Bocciardi, Federico Zara, Carlo Castellani, Luis J. V. Galietta, Shafagh A. Waters, Alexandre Hinzpeter, Nicoletta Pedemonte   +25 more
wiley   +1 more source

Cutaneous Adverse Effects of Elexacaftor‐Tezacaftor‐Ivacaftor: A Single Center Cohort Study on Acne Severity in Adults With Cystic Fibrosis

Journal of Cosmetic Dermatology, Volume 24, Issue 11, November 2025.
Aaron D. Smith, Catherine E. Lyons, Lindsay Somerville, R. Hal Flowers, Emily Kaplan, Dana Albon   +5 more
wiley   +1 more source

Demonstrating Bioequivalence for a Lumacaftor Monosubstance Formulation Versus Orkambi® (Lumacaftor/Ivacaftor) in Healthy Subjects

Drugs in R&D
Lumacaftor is an active ingredient in the US Food and Drug Administration-approved combination medication Orkambi®, which is used for treating cystic fibrosis. Experimental evidence suggests that lumacaftor can be used as a monotherapy to improve brain perfusion and memory in heart failure.
Alexandra Papaelias, Darcy Lidington, Steffen-Sebastian Bolz   +2 more
openaire   +3 more sources

In Silico Evaluation of Lumacaftor for Cystic Fibrosis

PARIPEX INDIAN JOURNAL OF RESEARCH
Abstract Cystic fibrosis is a common life-limiting autosomal recessive genetic disorder that causes severe damage to lungs, digestive system and other organs in the body. This disease is a result of mutation in a gene that encodes for chloride-conducting transmembrane channel called CFTR, which in turn regulates mucociliary clearance and anion ...
openaire   +1 more source

Variation in Use of Lumacaftor/Ivacaftor [PDF]

D37. A PULMONARY AND CRITICAL CARE MEDLEY, 2020
openaire   +1 more source

Lumacaftor/ivacaftor for cystic fibrosis

, 2019
openaire   +1 more source

Lumacaftor/ivacaftor for cystic fibrosis.

Australian prescriber
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Ivacaftor/lumacaftor

Reactions Weekly, 2019
  +8 more sources

Ivacaftor/lumacaftor

Reactions Weekly, 2017
  +9 more sources